Tokio Marine Asset Management Co. Ltd. Invests $385,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Tokio Marine Asset Management Co. Ltd. purchased a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the fourth quarter, HoldingsChannel reports. The fund purchased 13,051 shares of the company’s stock, valued at approximately $385,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Polar Capital Holdings Plc grew its holdings in shares of Mirum Pharmaceuticals by 27.0% during the third quarter. Polar Capital Holdings Plc now owns 1,175,000 shares of the company’s stock worth $37,130,000 after buying an additional 250,000 shares in the last quarter. Raymond James & Associates grew its holdings in shares of Mirum Pharmaceuticals by 57.1% during the third quarter. Raymond James & Associates now owns 106,207 shares of the company’s stock worth $3,356,000 after buying an additional 38,619 shares in the last quarter. Rafferty Asset Management LLC grew its holdings in shares of Mirum Pharmaceuticals by 18.4% during the third quarter. Rafferty Asset Management LLC now owns 137,205 shares of the company’s stock worth $4,336,000 after buying an additional 21,312 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Mirum Pharmaceuticals by 210.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 224,571 shares of the company’s stock worth $7,096,000 after buying an additional 152,287 shares in the last quarter. Finally, Genworth Financial Inc purchased a new stake in shares of Mirum Pharmaceuticals during the fourth quarter worth about $385,000.

Mirum Pharmaceuticals Stock Down 0.1 %

Shares of MIRM stock opened at $24.46 on Monday. The company has a quick ratio of 4.19, a current ratio of 4.45 and a debt-to-equity ratio of 1.23. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $35.56. The firm’s 50 day moving average price is $26.42 and its two-hundred day moving average price is $28.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). The business had revenue of $69.55 million for the quarter, compared to analyst estimates of $66.73 million. Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. Research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. SVB Leerink lowered their price target on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating for the company in a report on Monday, March 18th. HC Wainwright restated a “buy” rating and issued a $58.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, April 2nd. Stifel Nicolaus began coverage on shares of Mirum Pharmaceuticals in a report on Wednesday, April 17th. They issued a “buy” rating and a $48.00 target price for the company. JMP Securities boosted their target price on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, March 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $35.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, February 29th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $51.70.

Insider Transactions at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 4,303 shares of the business’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $25.80, for a total transaction of $111,017.40. Following the transaction, the chief operating officer now directly owns 29,013 shares of the company’s stock, valued at $748,535.40. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, COO Peter Radovich sold 4,303 shares of the business’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $25.80, for a total transaction of $111,017.40. Following the transaction, the chief operating officer now directly owns 29,013 shares of the company’s stock, valued at $748,535.40. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Eric Bjerkholt bought 2,000 shares of Mirum Pharmaceuticals stock in a transaction dated Wednesday, March 27th. The shares were purchased at an average cost of $24.80 per share, for a total transaction of $49,600.00. Following the completion of the transaction, the chief financial officer now owns 14,000 shares of the company’s stock, valued at approximately $347,200. The disclosure for this purchase can be found here. Corporate insiders own 24.06% of the company’s stock.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.